A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Status:
Completed
Trial end date:
2021-08-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of single
agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel,
docetaxel, pembrolizumab or cetuximab in selected advanced gastrointestinal and genitourinary
tumors.